17:55 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting don't shed much light on outstanding questions related to the company's data reports from the trial, but do...
17:46 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
21:49 , Dec 4, 2018 |  BC Extra  |  Clinical News

Legend reports 15 months PFS for anti-BCMA CAR; questions over trial sites linger

Data presented on the most advanced Chinese CAR product at the American Society of Hematology (ASH) meeting on Monday don't shed much light on outstanding questions related to the company's data reports from the trial,...
00:51 , Dec 4, 2018 |  BC Extra  |  Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed...
20:37 , Aug 23, 2018 |  BC Extra  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
23:31 , Jun 18, 2018 |  BC Extra  |  Politics & Policy

Payers, drugmakers face off over CAR T Medicare coverage

CMS is receiving contradictory recommendations in response to its request for comments about creating a national policy on Medicare payments for CAR T cancer therapies. Payers' and patient advocacy groups' comments urged CMS to institute...
15:27 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

bluebird reports updated Phase I data for bb2121 in MM

bluebird bio Inc. (NASDAQ:BLUE) reported updated data from the Phase I CRB-401 trial evaluating its CAR T cell therapy bb2121 in patients with relapsed or refractory multiple myeloma. The data were presented at the American...